Serum peptide pattern that differentially diagnoses hepatitis <scp>B</scp> virus‐related hepatocellular carcinoma from liver cirrhosis

Wang, Na; Cao, Yuan; Song, Wei; He, Kun; Li, Tao; Wang, Jie; Xu, Bin; Si, Haiyan; Hu, Chengjin; Li, Ailing

doi:10.1111/jgh.12545

Cited by 14 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human low molecular weight (1–10 KDa) serum peptidome includes many cytokines, peptide hormones, endogenous peptide products, and protein fragments, some of which may be uniquely suited for diagnostic, prognostic, or predictive peptide biomarker discovery [18,24–28]. In other words, the serum peptidome contains an enormous wealth of unexplored biomarker information.…”

Section: Discussionmentioning

confidence: 99%

Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma

Wang

Tang

et al. 2017

PLoS ONE

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough pemetrexed plus cis/carboplatin has become the most effective chemotherapy regimen for patients with advanced lung adenocarcinoma, predictive biomarkers are not yet available, and new tools to identify chemosensitive patients who would likely benefit from this treatment are desperately needed. In this study, we constructed and validated predictive peptide models using the serum peptidome profiles of two datasets.MethodsOne hundred eighty-three patients treated with first-line platinum-based pemetrexed treatment for advanced lung adenocarcinoma were retrospectively enrolled and randomized into the training (n = 92) or validation (n = 91) set, and pre-treatment serum samples were analyzed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and ClinProTools software. Serum peptidome profiles from the training set were used to identify potential predictive peptide biomarkers and construct a predictive peptide model for accurate group discrimination; which was then used to classify validation samples into “good” and “poor” outcome groups. The clinical outcomes of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were analyzed based on the classification result.ResultsEight potential peptide biomarkers were identified. A predictive peptide model based on four distinct m/z features (2,142.12, 3,316.19, 4,281.94, and 6,624.02 Da) was developed based on the clinical outcomes of training set patients after first-line pemetrexed plus platinum treatment. In the validation set, the good group had significantly higher ORR (49.1% vs. 8.3%, P <0.001) and DCR (96.4% vs. 47.2%, P <0.001), and longer PFS (7.3 months vs. 2.7 months, P <0.001) vs. the poor group. However, the model did not predict OS (13.6 months vs. 12.7 months, P = 0.0675).ConclusionOur predictive peptide model could predict pemetrexed plus platinum treatment outcomes in patients with advanced lung adenocarcinoma and might thus facilitate appropriate patient selection. Further studies are needed to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma

Wang

Tang

et al. 2017

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…Liu et al 2018 [46] Japan Saito et al 2016 [47] 1 H NMR Early stage vs Advanced stage HCC Italy Casadei-Gardini et al 2020 [48] Virus France Goossens et al 2016 [49] Heath control/Cirrhosis France Fages et al 2015; Nahon et al 2012 [50,51]…”

Section: Francementioning

confidence: 99%

Metabolomic biomarkers for hepatocellular carcinoma

Feng

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is a highly malignant cancer which lack of effective diagnosis and prognosis biomarkers, therefore surging studies focused on the metabolite candidates for HCC. The current study was designed to systematically review the metabolic studies for HCC, summarize the current available evidence and provide implication for further studies within this area. By systematically screening Pubmed and Embase, and eligibility assessment, we eventually included 55 pieces of studies. After summarized their characteristics, we reviewed them by 3 parts, regarding to the different biofluid they carried out the experiments. By collecting the candidates from all the included studies, we carried out pathway enrichment to see the representative of the reported candidates, as expected the pathway consistent with the current knowledge of HCC. Next, we conduct quality assessment on the included studies. Only 36% of the current evidence grouped as high quality, indicating the quality of metabolic studies needs further improvement.

show abstract

“…Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, ranking fourth in terms of cancer mortality worldwide [1]. Currently, numerous serum markers are used for HCC detection in clinical terms, such as AFP [95], but the sensitivity and specificity of AFP for the detection of HCC at an early stage are unsatisfactory [96,97]. Thus, noninvasive and effective diagnostic and prognostic biomarkers for early detection are urgently needed.…”

Section: Hepatocellular Cancermentioning

confidence: 99%

Circulating MicroRNAs in Gastrointestinal Cancer

Ohtsuka

Iwamoto

Naito

et al. 2021

Cancers

View full text Add to dashboard Cite

Gastrointestinal cancer (GIC) is a common disease and is considered to be the leading cause of cancer-related death worldwide; thus, new diagnostic and therapeutic strategies for GIC are urgently required. Noncoding RNAs (ncRNAs) are functional RNAs that are transcribed from the genome but do not encode proteins. MicroRNAs (miRNAs) are short ncRNAs that are reported to function as both oncogenes and tumor suppressors. Moreover, several miRNA-based drugs are currently proceeding to clinical trials for various diseases, including cancer. In recent years, the stability of circulating miRNAs in blood has been demonstrated. This is of interest because these miRNAs could be potential noninvasive biomarkers of cancer. In this review, we focus on circulating miRNAs associated with GIC and discuss their potential as novel biomarkers.

show abstract

Serum peptide pattern that differentially diagnoses hepatitis B virus‐related hepatocellular carcinoma from liver cirrhosis

Abstract: Our results indicate that the MLP model is a novel and useful serum peptide pattern for distinguishing HCC and LC. The peptidome signature alone or together with serum AFP determination may be a more effective method for early diagnosis of HCC in patients with HBV-related LC.

Cited by 14 publications

References 33 publications

Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma

Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma

Metabolomic biomarkers for hepatocellular carcinoma

Circulating MicroRNAs in Gastrointestinal Cancer

Contact Info

Product

Resources

About